![]() "Today's acquisition makes sense as it adds a novel testing technology that is modular and scalable," Vontobel analyst Stefan Scheider said in a research note. The use of multiple panels allows for inclusion of a wider range of targets, but the selection of the appropriate panel or panels depends upon accurate Gram stain results. The tests were also useful for "the rapid identification of bloodstream infections and the detection of antimicrobial resistance genes, (which) are more essential than ever for hospitals and their patients," Schinecker said. The GenMark Dx ePlex system utilizes three panels for identification of Gram-positive, Gram-negative, and fungal organisms, all of which are now commercially available. Roche, the world's top cancer drug maker, already counts a large number of various tests for the virus, but said testing using the GenMark respiratory pathogen panels would be a welcome complement to its existing portfolio. The current pandemic, which has killed some 2.65 million people worldwide since the first cases were detected in China in late 2019, has spurred huge demand for rapid tests. GenMark says its so-called syndromic panel tests can quickly identify the most common viral and bacterial organisms linked to upper respiratory infection, including SARS-CoV-2, the virus that causes COVID-19. The deal, subject to regulatory approval, should be concluded in the second quarter, the company said. Healthcare giant Roche Holding ( RHHBY 0.81) recently announced plans to acquire GenMark Diagnostics ( GNMK) in a deal valued at. "Acquiring GenMark Diagnostics will broaden our molecular diagnostics portfolio," Roche chief Thomas Schinecker said in the statement. GenMark appears to be a good fit for Roche's diagnostics business. GenMark makes molecular tests that can establish the presence of several different pathogens from just one sample, Monday's statement said. Roche is offering $24.05 a share for GenMark, a premium of some 43% to its last quoted share price on February 10. ![]() ![]() The Swiss company said it had signed a "definitive merger agreement" with the California-based firm after both boards approved the all-cash deal. firm GenMark Diagnostics and thus broaden its rapid test portfolio, including for COVID-19. Although GenMark has not announced the specific targets for these assays, clinical laboratories will view with great interest how they compare with current options. Swiss pharma giant Roche said Monday it would pay US$1.8 billion (1.5 billion euros) to buy U.S. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |